According to some estimates, gastrointestinal symptoms including bloating, nausea, vomiting, abdominal pain and feeling full after little has been eaten are present in up to 75 percent of people with type 1. When these stomach problems are the result of neuropathy, the condition is called gastroparesis. The condition is clinically under-recognized and hard to treat even after it is identified.
Since 1981, the pharmaceutical company Janssen Pharceutica has made the research drug domperidone available to patients when the currently available drugs are ineffective. The study shows that 12 months of domperidone therapy results in sustained improvement of these symptoms. It also reduced the need for hospitalization from nausea and vomiting by one-third. The drug has been available in other countries for years and, pending FDA approval, could be available in the United States by next year.